CCXI Summary

  1. NASDAQ
  2. >
  3. CCXI
TickerCCXI
DescriptionCHEMOCENTRYX INC
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
ExchangeNASDAQ
TypeStock
SectorHealthcare
Next Earnings DateMarch 7th, 2022
IV79.687066%
IV Percentile34th
IV Rank7.92%
IV Skew1.316717
IV Skew Percentile59th
IV Skew SentimentNeutral
Option Volume5,368
Volume2,016,506
Price$32.60
Previous Close$33.31
52-Week High$70.29
52-Week Low$9.53
50-Day Moving Avg.$35.67
200-Day Moving Avg.$25.86
10-Day Avg. Volume1,422,352
20-Day Avg. Volume1,349,438
30-Day Avg. Volume1,363,641
3-Month Avg. Volume1,505,553
EPS-$1.75
Outstanding Shares69,900,000
Market Capitalization$2,265,517,800
CurrencyUSD
UpdatedJanuary 14th, 2022